Survodutide meets Phase III goals in diabetes

Lundbeck has randomized the first patient in the Phase II DARE2 trial of its oral Parkinson's candidate Lu AF28996. In an interview with NLS, Tarek Samad, Head of R&D, explains what the trial needs to show to justify Phase III and where the drug could fit alongside existing treatments.

Genmab has reported Phase 2 results for its antibody-drug conjugate rinatabart sesutecan (Rina-S) in platinum-resistant ovarian cancer, with a confirmed objective response rate of 45.9% among 109 treated patients.

Lundbeck has reported headline results from the Phase IV THRIVE trial, in which 60% of migraine patients who had responded inadequately to a prior CGRP-targeting preventive therapy reported being "much" or "very much" improved after 24 weeks on Vyepti (eptinezumab).

Stockholm-based Atrogi has reported positive human data for ATR-258, its first-in-class oral therapy designed to improve muscle function and body composition. Over eight weeks, treatment was associated with an approximately 13% improvement in lower-extremity muscle power, together with more lean mass and less fat mass.

Stockholm-based Mendus has presented updated five-year follow-up data from its completed ADVANCE II trial in acute myeloid leukemia (AML). It also gave an update on the ongoing VITAL-CML trial of its immunotherapy vididencel in chronic myeloid leukemia (CML). The data were presented at the Second Bologna Workshop on Immunotherapy for AML in Italy.

Södertälje-based Anocca has dosed the first patient in Sweden with its TCR-T cell therapy, which targets KRAS G12V mutations in pancreatic cancer. Sweden is the third European country where a patient has received the therapy.

All planned patient visits have now been completed in the company's Phase III HEEALING1 study of linaprazan glurate in erosive GERD. Topline results are still expected in Q4 2026.